Previous in vitro studies have shown that Gsα mutations upregulate Receptor activator of nuclear factor-kappa B ligand expression in FD.[6] Thus, denosumab may be useful in the treatment of FD and deserves further investigation. The gene discussed is GNAS; the disease is Fabry disease.